# Regulatory Strategy Memo: Prescribing Prescription Assistant

## Objective
Define the lowest-friction regulatory path for a U.S. specialty ambulatory prescribing Prescription Assistant in 2026 and translate that into practical product strategy.

## Executive Recommendation
The product should be built, positioned, and sold as an `explainable clinician-facing Prescription Assistant`, not as an `AI prescription tool`. In the 2026 clinic environment, that is the strongest path to faster deployment, lighter FDA exposure, and smoother enterprise adoption. The product should help clinicians assess whether a therapy is realistically startable, surface the main access barriers, suggest feasible alternatives, and support patient communication. It should not autonomously choose therapy, execute prescription changes, or submit downstream transactions based solely on AI output.

## Regulatory Read
- `FDA`: The revised 2026 CDS environment appears relatively favorable for clinician-facing software that provides recommendations rather than directives and allows independent clinician review. Explainability is the key boundary condition.
- `HIPAA / security`: This is likely the biggest real-world enterprise hurdle. Health systems will expect BAA readiness, PHI controls, logging, subprocessor governance, and clear retention/deletion practices.
- `OCR / Section 1557`: Because the product influences patient care pathways, buyers will expect evidence that discriminatory risk has been identified, monitored, and mitigated.
- `ONC / HTI-1 expectations`: Even if not directly binding in all cases, certified EHR environments will increasingly expect source transparency, model governance, and change-management artifacts.
- `FTC`: Marketing and sales claims must stay tightly aligned to substantiated workflow and operational value, not exaggerated AI promises.

## What Keeps Regulation Manageable
To remain on the lighter-regulation side, the product should:
- support clinician judgment rather than replace it
- present options and rationale rather than commands
- show the basis for each recommendation, including key drivers and source freshness
- focus on `access feasibility`, not `clinical superiority`
- avoid hidden logic and black-box outputs
- avoid automatic substitution, routing, or PA submission

The product becomes materially riskier if it starts to look like it is deciding which drug the patient should receive, especially if the reasoning is opaque or the recommendation is operationalized automatically.

## Product Strategy Implications
The current wedge is directionally right. The best phase 1 product is:
- `accessibility assessment`: explain likely barriers such as PA burden, formulary friction, out-of-pocket exposure, and routing constraints
- `executable alternatives`: show clinically appropriate, lower-friction options with clear rationale
- `communication support`: help the clinician set realistic patient expectations during the visit

This regulatory landscape strengthens a prescriber-first wedge and argues against early expansion into:
- autonomous therapy selection
- coordinator workbench replacement
- one-click routing orchestration
- auto-generated medical necessity arguments without review
- patient-facing autonomous AI guidance

## Success Guidelines
- Position the product as an `access intelligence layer` or `prescription Prescription Assistant`.
- Make explainability a visible product feature, not only a compliance artifact.
- Prefer `several feasible options` over a single "best answer."
- Constrain alternatives to guideline-consistent or customer-approved therapy options.
- Keep write actions user-initiated and reviewable.
- Build an early enterprise diligence pack: BAA posture, security overview, subprocessor list, AI transparency sheet, validation summary, bias-risk policy, and model change policy.
- Prove value through operational outcomes such as `time to therapy`, `first-fill success`, and `rework reduction`, not strong claims about guaranteed coverage or prescribing accuracy.

## Strategic Conclusion
In 2026, the winning strategy is not to make the product more autonomous. It is to make it deeply useful while remaining visibly subordinate to clinician judgment. An explainable prescribing Prescription Assistant is both the safer regulatory posture and the better initial go-to-market strategy for large specialty ambulatory organizations.
